search
Back to results

Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma

Primary Purpose

Hodgkin Lymphoma

Status
Active
Phase
Phase 2
Locations
International
Study Type
Interventional
Intervention
brentuximab vedotin
doxorubicin
vinblastine
dacarbazine
G-CSF
nivolumab
Sponsored by
Seagen Inc.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Hodgkin Lymphoma focused on measuring Brentuximab vedotin, Doxorubicin, Vinblastine, Dacarbazine, Nivolumab, Seattle Genetics

Eligibility Criteria

12 Years - undefined (Child, Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria

  • Treatment-naïve, classic Hodgkin lymphoma (cHL) participants

    • Participants enrolling in Part A of the study must have Ann Arbor Stage III or IV disease
    • Participants enrolling in Part B of the study must have Ann Arbor Stage I or II cH: with bulky mediastinal disease, or Stage III or IV
    • Participants enrolling in Part C of the study must have Ann Arbor Stage I or II cHL without bulky disease
  • Histologically confirmed cHL according to the current World Health Organization (WHO) Classification
  • Bidimensional measurable disease as documented by PET/CT or CT imaging
  • Age 12 years or older in the United States. For regions outside of the US, participants must 18 years or older.
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2

Exclusion Criteria

  • Nodular lymphocyte predominant HL
  • History of another malignancy within 3 years of the first dose of study drug or any evidence of residual disease from a previously diagnosed malignancy. Exceptions are malignancies with a negligible risk or metastasis or death. Participants with nonmelanoma skin cancer, localized prostate cancer, or carcinoma in situ of any type are not excluded if they have undergone complete resection
  • Prior immunosuppressive chemotherapy, therapeutic radiation, or any immunotherapy within 4 weeks of the first study drug dose
  • Prior treatment with an anti-PD-1, anti-PD-L1, anti-PD-L2, or anti-CTLA-4 antibody, or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways
  • Active cerebral/meningeal disease related to the underlying malignancy
  • Any active Grade 3 or higher viral, bacterial, or fungal infection within two weeks of the first dose of study drug (Grade 3 defined by the National Cancer Institute's Common Terminology Criteria for Adverse Events, NCI CTCAE Version 4.03)
  • Current therapy with other systemic anti-neoplastic or investigational agents
  • Planned consolidative radiotherapy (Parts B and C only)
  • Active interstitial lung disease that is symptomatic or may interfere with the detection or management of suspected drug-related pulmonary toxicity (Parts B and C only)
  • Grade 3 or higher pulmonary disease unrelated to underlying malignancy
  • Documented history of idiopathic interstitial pneumonia or diffusing capacity of the lung for carbon monoxide <50% predicted
  • History of a cerebral vascular event within 6 months of first dose of study drug
  • Child-Pugh B or C hepatic impairment
  • Grade 2 or higher peripheral sensory or motor neuropathy
  • Participants with acute or chronic graft-versus-host-disease (GvHD) or receiving immunosuppressive therapy as treatment or as prophylaxis against GvHD
  • Previous treatment with brentuximab vedotin
  • Participants who are pregnant or breastfeeding
  • Other serious condition that would impair the participant's ability to receive or tolerate the planned treatment and follow-up

Sites / Locations

  • Compassionate Care Research Group
  • Rocky Mountain Cancer Centers - Aurora
  • University of Colorado Health Memorial Hospital
  • Cancer Centers of Colorado - Denver
  • Poudre Valley Health System (PVHS)
  • SCL Health - St. Mary's Hospital & Medical Center
  • Miami Cancer Institute at Baptist Health, Inc.
  • Florida Cancer Specialists - North Region
  • Cardinal Bernardin Cancer Center / Loyola University Medical Center
  • Illinois Cancer Specialists
  • Illinois Cancer Care
  • Massachusetts General Hospital
  • Beth Israel Deaconess Medical Center
  • Karmanos Cancer Institute / Wayne State University
  • Henry Ford Health System
  • Minnesota Oncology Hematology P.A.
  • Washington University in St Louis
  • New Jersey Hematology Oncology Associates, LLC
  • Regional Cancer Care Associates - Freehold
  • Hackensack University Medical Center
  • Regional Cancer Care Associates - Howell
  • Morristown Medical Center/ Carol G. Simon Cancer Center
  • Regional Cancer Care Associates - Mount Holly
  • Regional Cancer Care Associates - Central Jersey
  • Regional Cancer Care Associates - Sparta
  • New York Oncology Hematology, P.C.
  • CareMount Medical Group
  • Mount Sinai Medical Center
  • Memorial Sloan Kettering Cancer Center
  • Clinical Research Alliance - Abraham Mittelman, MD, LLC
  • Clinical Research Alliance - Morton Coleman, MD
  • Wake Forest Baptist Medical Center / Wake Forest University
  • Oncology Hematology Care
  • Case Western Reserve University / University Hospitals Cleveland Medical Center
  • Cleveland Clinic, The
  • Toledo Clinic Cancer Center
  • Willamette Valley Cancer Institute and Research Center
  • Providence Portland Medical Center
  • Medical University of South Carolina/Hollings Cancer Center
  • University of Tennessee
  • Tennessee Oncology-Nashville/Sarah Cannon Research Institute
  • Texas Oncology - Austin Midtown
  • Texas Oncology - Medical City Dallas
  • Texas Oncology - Flower Mound
  • Brooke Army Medical Center
  • Texas Oncology - Fort Worth 12th Avenue
  • MD Anderson Cancer Center / University of Texas
  • Texas Oncology - San Antonio Medical Center
  • Texas Oncology - Northeast Texas
  • Huntsman Cancer Institute/University of Utah
  • Virginia Cancer Specialists, PC
  • Oncology and Hematology Assoc of SW VA DBA Blue Ridge Cancer Care
  • Kadlec Clinic Hematology and Oncology
  • Vista Oncology Inc PS
  • Seattle Cancer Care Alliance / University of Washington
  • Royal Adelaide Hospital
  • Ballarat Regional Integrated Cancer Care
  • Monash Medical Centre
  • Epworth Healthcare
  • Fakultni nemocnice Hradec Kralove-oddeleni klinicke hematologie
  • Fakultni Nemocnice Kralovske Vinohrady
  • Azienda Ospedaliera Spedali Civili di Brescia
  • IRCSS Policlinico San Matteo
  • Azienda Ospedaliera Universitaria Senese
  • Azienda Ospedaliera Citta della Salute e della Scienza di Torino
  • Pratia MCM Krakow
  • Hospital del Mar
  • Hospital Universitario Vall d'Hebron
  • Institut Catala d'Oncologia - Hospital Duran i Reynals (ICO L'Hospitalet)
  • Hospital Universitario de Girona Doctor Josep Trueta
  • Hospital Universitario Fundacion Jimenez Diaz
  • Hospital Universitario 12 de Octubre
  • Hospital Puerta de Hierro Majadahonda
  • Hospital Universitario Central de Asturias
  • Hospital Clinico Universitario de Salamanca
  • Hospital Universitari i Politecnic La Fe de Valencia

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Experimental

Experimental

Experimental

Arm Label

Part A: A+AVD

Part B: AN+AD

Part C: AN+AD

Arm Description

Brentuximab vedotin (A) plus doxorubicin (+A), vinblastine (V), and dacarbazine (D) administered by intravenous (IV) infusion in participants with advanced stage classical Hodgkin lymphoma (cHL) during each treatment cycle.

Brentuximab vedotin (A) plus nivolumab (N), doxorubicin (+A), and dacarbazine (D) administered separately by IV infusion in participants with Stage II bulky mediastinal disease and Stage III or IV cHL during each treatment cycle.

Brentuximab vedotin (A) plus nivolumab (N), doxorubicin (+A), and dacarbazine (D) administered separately by IV infusion in participants with Stage I or II cHL with non-bulky mediastinal disease during each treatment cycle.

Outcomes

Primary Outcome Measures

Febrile Neutropenia (FN) Rate (Part A)
Proportion of patients with treatment-emergent incidence of FN.
Complete response (CR) rate (Parts B and C)
Proportion of participants with CR at end of treatment (EOT), according to the Lymphoma Response to Immunomodulatory Therapy Criteria (LYRIC).

Secondary Outcome Measures

Primary Refractory Disease Rate (Part A)
Proportion of participants with less than CR or relapse within 3 months of EOT.
CR Rate (Part A)
Proportion of patients with CR at EOT.
Physician-reported Progression Free Survival (PFS) (Part A)
The physician-reporting PFS is defined as the time from start of study treatment to first documentation of progression per investigator or to death due to any cause, whichever comes first.
Subsequent Anticancer Therapy Utilization Rate (Part A)
Proportion of patients with subsequent anticancer therapies.
Mean Dose Intensity (Part A)
Rate of Dose Reduction and Delays (Part A)
Proportion of patients with dose reductions or delays related to any component of A+AVD.
Incidence of adverse events (Parts B and C)
Incidence of laboratory abnormalities (Parts B and C)
Overall response rate (ORR) at EOT (Parts B and C)
ORR is defined as the proportion of participants with CR or partial response (PR) at EOT.
Duration of response (DOR) (Parts B and C)
DOR is defined as the time from the first documentation of objective tumor response (CR or PR) to the first documentation of tumor progression per LYRIC or death, whichever comes first.
Duration of complete response (DOCR) (Parts B and C)
DOCR is defined as the time from the first documentation of complete tumor response (CR) to the first documentation of tumor progression per LYRIC or death, whichever comes first. DOCR will only be calculated for the subgroup of subjects achieving CR.
Event-free survival (EFS) (Parts B and C)
EFS is defined as the time from start of study treatment to the first documentation of objective tumor progression, death due to any cause, or receipt of subsequent anticancer therapy to treat residual or progressive disease, whichever comes first.
PFS (Parts B and C)
PFS is defined as the time from start of study treatment to first documentation of objective tumor progression or death.
Overall survival (OS) (Parts B and C)
Overall survival is defined as the time from start of study treatment to the date of death due to any cause.

Full Information

First Posted
August 22, 2018
Last Updated
August 11, 2023
Sponsor
Seagen Inc.
Collaborators
Bristol-Myers Squibb
search

1. Study Identification

Unique Protocol Identification Number
NCT03646123
Brief Title
Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma
Official Title
Multiple Part Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma Subjects
Study Type
Interventional

2. Study Status

Record Verification Date
August 2023
Overall Recruitment Status
Active, not recruiting
Study Start Date
January 28, 2019 (Actual)
Primary Completion Date
November 7, 2022 (Actual)
Study Completion Date
June 7, 2026 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Seagen Inc.
Collaborators
Bristol-Myers Squibb

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
This trial will study two treatment combinations for classical Hodgkin lymphoma (cHL). This trial will find out if these two treatment combinations work to treat cHL. It will also find out what side effects occur. A side effect is anything the drug does besides treating cancer. This study will have three parts (Parts A, B, and C). The drugs used in Part A are a combination of targeted anticancer drug (brentuximab vedotin) and three chemotherapy drugs (doxorubicin, vinblastine, and dacarbazine). These four drugs are called "A+AVD." Participants will be treated with granulocyte colony stimulating factor (G-CSF) following every dose of A+AVD for 6 cycles of treatment (12 doses). Part A will look at whether the A+AVD drug combination reduces the number of participants who experience the side effect of febrile neutropenia. Febrile neutropenia is a very low white blood cell count and a fever, which can be life threatening. Parts B and C will use drug combination of brentuximab vedotin, plus nivolumab, doxorubicin, and dacarbazine. These four drugs are called "AN+AD." Parts B and C will study how well the drugs work to treat cHL and what side effects they cause.
Detailed Description
This study will have three parts. Part A of the study is designed to evaluate the incidence of febrile neutropenia, efficacy, and dose intensity in participants with advanced stage classical Hodgkin lymphoma (cHL) receiving granulocyte colony stimulating factor primary prophylaxis (G-PP) administration during treatment with frontline A+AVD. In Part A, participants will be treated with granulocyte colony stimulating factor (G-CSF) following every dose of A+AVD for 6 cycles of treatment. Participants will be treated using institutional standard of care practices for the majority of treatment decisions. Part B is designed to evaluate the combination of brentuximab vedotin, nivolumab, doxorubicin, and dacarbazine (AN+AD) as frontline treatment in participants with advanced cHL. In Part B, participants will be given AN+AD combination for 6 cycles of treatment. This part of the trial will look at whether this combination of drugs is effective and tolerable in participants with Stage II with bulky mediastinal disease and Stage III or IV cHL. Part C is designed to evaluate AN+AD as frontline treatment in participants with early stage cHL. In Part C, participants will be given AN+AD combination for 4 cycles of treatment. This part of the trial will look at whether this combination of drugs is effective and tolerable in participants with Stage I or II cHL with non-bulky mediastinal disease.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hodgkin Lymphoma
Keywords
Brentuximab vedotin, Doxorubicin, Vinblastine, Dacarbazine, Nivolumab, Seattle Genetics

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
255 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Part A: A+AVD
Arm Type
Experimental
Arm Description
Brentuximab vedotin (A) plus doxorubicin (+A), vinblastine (V), and dacarbazine (D) administered by intravenous (IV) infusion in participants with advanced stage classical Hodgkin lymphoma (cHL) during each treatment cycle.
Arm Title
Part B: AN+AD
Arm Type
Experimental
Arm Description
Brentuximab vedotin (A) plus nivolumab (N), doxorubicin (+A), and dacarbazine (D) administered separately by IV infusion in participants with Stage II bulky mediastinal disease and Stage III or IV cHL during each treatment cycle.
Arm Title
Part C: AN+AD
Arm Type
Experimental
Arm Description
Brentuximab vedotin (A) plus nivolumab (N), doxorubicin (+A), and dacarbazine (D) administered separately by IV infusion in participants with Stage I or II cHL with non-bulky mediastinal disease during each treatment cycle.
Intervention Type
Drug
Intervention Name(s)
brentuximab vedotin
Other Intervention Name(s)
Adcetris, SGN-35
Intervention Description
1.2 mg/kg by IV infusion
Intervention Type
Drug
Intervention Name(s)
doxorubicin
Intervention Description
25 mg/m^2 by IV infusion
Intervention Type
Drug
Intervention Name(s)
vinblastine
Intervention Description
6 mg/m^2 by IV infusion
Intervention Type
Drug
Intervention Name(s)
dacarbazine
Intervention Description
375 mg/m^2 by IV infusion
Intervention Type
Drug
Intervention Name(s)
G-CSF
Other Intervention Name(s)
filgrastim, pegfilgrastim
Intervention Description
Granulocyte colony stimulating factor (G-CSF) primary prophylaxis administered 24-36 hours after each dose of A+AVD
Intervention Type
Drug
Intervention Name(s)
nivolumab
Other Intervention Name(s)
Opdivo
Intervention Description
240 mg by IV infusion
Primary Outcome Measure Information:
Title
Febrile Neutropenia (FN) Rate (Part A)
Description
Proportion of patients with treatment-emergent incidence of FN.
Time Frame
Up to 6 months
Title
Complete response (CR) rate (Parts B and C)
Description
Proportion of participants with CR at end of treatment (EOT), according to the Lymphoma Response to Immunomodulatory Therapy Criteria (LYRIC).
Time Frame
Up to 6 months
Secondary Outcome Measure Information:
Title
Primary Refractory Disease Rate (Part A)
Description
Proportion of participants with less than CR or relapse within 3 months of EOT.
Time Frame
Up to 9 months
Title
CR Rate (Part A)
Description
Proportion of patients with CR at EOT.
Time Frame
Up to 6 months
Title
Physician-reported Progression Free Survival (PFS) (Part A)
Description
The physician-reporting PFS is defined as the time from start of study treatment to first documentation of progression per investigator or to death due to any cause, whichever comes first.
Time Frame
Up to 2 years
Title
Subsequent Anticancer Therapy Utilization Rate (Part A)
Description
Proportion of patients with subsequent anticancer therapies.
Time Frame
Up to 2.5 years
Title
Mean Dose Intensity (Part A)
Time Frame
Up to 6 months
Title
Rate of Dose Reduction and Delays (Part A)
Description
Proportion of patients with dose reductions or delays related to any component of A+AVD.
Time Frame
Up to 6 months
Title
Incidence of adverse events (Parts B and C)
Time Frame
Up to 7 months
Title
Incidence of laboratory abnormalities (Parts B and C)
Time Frame
Up to 7 months
Title
Overall response rate (ORR) at EOT (Parts B and C)
Description
ORR is defined as the proportion of participants with CR or partial response (PR) at EOT.
Time Frame
Up to 6 months
Title
Duration of response (DOR) (Parts B and C)
Description
DOR is defined as the time from the first documentation of objective tumor response (CR or PR) to the first documentation of tumor progression per LYRIC or death, whichever comes first.
Time Frame
Up to 5 years
Title
Duration of complete response (DOCR) (Parts B and C)
Description
DOCR is defined as the time from the first documentation of complete tumor response (CR) to the first documentation of tumor progression per LYRIC or death, whichever comes first. DOCR will only be calculated for the subgroup of subjects achieving CR.
Time Frame
Up to 5 years
Title
Event-free survival (EFS) (Parts B and C)
Description
EFS is defined as the time from start of study treatment to the first documentation of objective tumor progression, death due to any cause, or receipt of subsequent anticancer therapy to treat residual or progressive disease, whichever comes first.
Time Frame
Up to 5 years
Title
PFS (Parts B and C)
Description
PFS is defined as the time from start of study treatment to first documentation of objective tumor progression or death.
Time Frame
Up to 5 years
Title
Overall survival (OS) (Parts B and C)
Description
Overall survival is defined as the time from start of study treatment to the date of death due to any cause.
Time Frame
Up to 5 years

10. Eligibility

Sex
All
Minimum Age & Unit of Time
12 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria Treatment-naïve, classic Hodgkin lymphoma (cHL) participants Participants enrolling in Part A of the study must have Ann Arbor Stage III or IV disease Participants enrolling in Part B of the study must have Ann Arbor Stage I or II cH: with bulky mediastinal disease, or Stage III or IV Participants enrolling in Part C of the study must have Ann Arbor Stage I or II cHL without bulky disease Histologically confirmed cHL according to the current World Health Organization (WHO) Classification Bidimensional measurable disease as documented by PET/CT or CT imaging Age 12 years or older in the United States. For regions outside of the US, participants must 18 years or older. Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2 Exclusion Criteria Nodular lymphocyte predominant HL History of another malignancy within 3 years of the first dose of study drug or any evidence of residual disease from a previously diagnosed malignancy. Exceptions are malignancies with a negligible risk or metastasis or death. Participants with nonmelanoma skin cancer, localized prostate cancer, or carcinoma in situ of any type are not excluded if they have undergone complete resection Prior immunosuppressive chemotherapy, therapeutic radiation, or any immunotherapy within 4 weeks of the first study drug dose Prior treatment with an anti-PD-1, anti-PD-L1, anti-PD-L2, or anti-CTLA-4 antibody, or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways Active cerebral/meningeal disease related to the underlying malignancy Any active Grade 3 or higher viral, bacterial, or fungal infection within two weeks of the first dose of study drug (Grade 3 defined by the National Cancer Institute's Common Terminology Criteria for Adverse Events, NCI CTCAE Version 4.03) Current therapy with other systemic anti-neoplastic or investigational agents Planned consolidative radiotherapy (Parts B and C only) Active interstitial lung disease that is symptomatic or may interfere with the detection or management of suspected drug-related pulmonary toxicity (Parts B and C only) Grade 3 or higher pulmonary disease unrelated to underlying malignancy Documented history of idiopathic interstitial pneumonia or diffusing capacity of the lung for carbon monoxide <50% predicted History of a cerebral vascular event within 6 months of first dose of study drug Child-Pugh B or C hepatic impairment Grade 2 or higher peripheral sensory or motor neuropathy Participants with acute or chronic graft-versus-host-disease (GvHD) or receiving immunosuppressive therapy as treatment or as prophylaxis against GvHD Previous treatment with brentuximab vedotin Participants who are pregnant or breastfeeding Other serious condition that would impair the participant's ability to receive or tolerate the planned treatment and follow-up
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Linda Ho, MD
Organizational Affiliation
Seagen Inc.
Official's Role
Study Director
Facility Information:
Facility Name
Compassionate Care Research Group
City
Fountain Valley
State/Province
California
ZIP/Postal Code
92708
Country
United States
Facility Name
Rocky Mountain Cancer Centers - Aurora
City
Aurora
State/Province
Colorado
ZIP/Postal Code
80012
Country
United States
Facility Name
University of Colorado Health Memorial Hospital
City
Colorado Springs
State/Province
Colorado
ZIP/Postal Code
80909
Country
United States
Facility Name
Cancer Centers of Colorado - Denver
City
Denver
State/Province
Colorado
ZIP/Postal Code
80218
Country
United States
Facility Name
Poudre Valley Health System (PVHS)
City
Fort Collins
State/Province
Colorado
ZIP/Postal Code
80528
Country
United States
Facility Name
SCL Health - St. Mary's Hospital & Medical Center
City
Grand Junction
State/Province
Colorado
ZIP/Postal Code
81501
Country
United States
Facility Name
Miami Cancer Institute at Baptist Health, Inc.
City
Miami
State/Province
Florida
ZIP/Postal Code
33176
Country
United States
Facility Name
Florida Cancer Specialists - North Region
City
Saint Petersburg
State/Province
Florida
ZIP/Postal Code
33705
Country
United States
Facility Name
Cardinal Bernardin Cancer Center / Loyola University Medical Center
City
Maywood
State/Province
Illinois
ZIP/Postal Code
60153
Country
United States
Facility Name
Illinois Cancer Specialists
City
Niles
State/Province
Illinois
ZIP/Postal Code
60714
Country
United States
Facility Name
Illinois Cancer Care
City
Peoria
State/Province
Illinois
ZIP/Postal Code
61615
Country
United States
Facility Name
Massachusetts General Hospital
City
Boston
State/Province
Massachusetts
ZIP/Postal Code
02114
Country
United States
Facility Name
Beth Israel Deaconess Medical Center
City
Boston
State/Province
Massachusetts
ZIP/Postal Code
02215
Country
United States
Facility Name
Karmanos Cancer Institute / Wayne State University
City
Detroit
State/Province
Michigan
ZIP/Postal Code
48201
Country
United States
Facility Name
Henry Ford Health System
City
Detroit
State/Province
Michigan
ZIP/Postal Code
48202
Country
United States
Facility Name
Minnesota Oncology Hematology P.A.
City
Edina
State/Province
Minnesota
ZIP/Postal Code
55435
Country
United States
Facility Name
Washington University in St Louis
City
Saint Louis
State/Province
Missouri
ZIP/Postal Code
63110
Country
United States
Facility Name
New Jersey Hematology Oncology Associates, LLC
City
Brick
State/Province
New Jersey
ZIP/Postal Code
08724
Country
United States
Facility Name
Regional Cancer Care Associates - Freehold
City
Freehold
State/Province
New Jersey
ZIP/Postal Code
07728
Country
United States
Facility Name
Hackensack University Medical Center
City
Hackensack
State/Province
New Jersey
ZIP/Postal Code
07601
Country
United States
Facility Name
Regional Cancer Care Associates - Howell
City
Howell
State/Province
New Jersey
ZIP/Postal Code
07731
Country
United States
Facility Name
Morristown Medical Center/ Carol G. Simon Cancer Center
City
Morristown
State/Province
New Jersey
ZIP/Postal Code
07960
Country
United States
Facility Name
Regional Cancer Care Associates - Mount Holly
City
Mount Holly
State/Province
New Jersey
ZIP/Postal Code
08060
Country
United States
Facility Name
Regional Cancer Care Associates - Central Jersey
City
Somerville
State/Province
New Jersey
ZIP/Postal Code
08876
Country
United States
Facility Name
Regional Cancer Care Associates - Sparta
City
Sparta
State/Province
New Jersey
ZIP/Postal Code
07871
Country
United States
Facility Name
New York Oncology Hematology, P.C.
City
Albany
State/Province
New York
ZIP/Postal Code
12208
Country
United States
Facility Name
CareMount Medical Group
City
Mount Kisco
State/Province
New York
ZIP/Postal Code
10549-3412
Country
United States
Facility Name
Mount Sinai Medical Center
City
New York
State/Province
New York
ZIP/Postal Code
10029
Country
United States
Facility Name
Memorial Sloan Kettering Cancer Center
City
New York
State/Province
New York
ZIP/Postal Code
10065
Country
United States
Facility Name
Clinical Research Alliance - Abraham Mittelman, MD, LLC
City
Purchase
State/Province
New York
ZIP/Postal Code
10577
Country
United States
Facility Name
Clinical Research Alliance - Morton Coleman, MD
City
Westbury
State/Province
New York
ZIP/Postal Code
11590
Country
United States
Facility Name
Wake Forest Baptist Medical Center / Wake Forest University
City
Winston-Salem
State/Province
North Carolina
ZIP/Postal Code
27157
Country
United States
Facility Name
Oncology Hematology Care
City
Cincinnati
State/Province
Ohio
ZIP/Postal Code
45242
Country
United States
Facility Name
Case Western Reserve University / University Hospitals Cleveland Medical Center
City
Cleveland
State/Province
Ohio
ZIP/Postal Code
44106
Country
United States
Facility Name
Cleveland Clinic, The
City
Cleveland
State/Province
Ohio
ZIP/Postal Code
44195
Country
United States
Facility Name
Toledo Clinic Cancer Center
City
Toledo
State/Province
Ohio
ZIP/Postal Code
43623
Country
United States
Facility Name
Willamette Valley Cancer Institute and Research Center
City
Eugene
State/Province
Oregon
ZIP/Postal Code
97401
Country
United States
Facility Name
Providence Portland Medical Center
City
Portland
State/Province
Oregon
ZIP/Postal Code
97213
Country
United States
Facility Name
Medical University of South Carolina/Hollings Cancer Center
City
Charleston
State/Province
South Carolina
ZIP/Postal Code
29425
Country
United States
Facility Name
University of Tennessee
City
Knoxville
State/Province
Tennessee
ZIP/Postal Code
37920
Country
United States
Facility Name
Tennessee Oncology-Nashville/Sarah Cannon Research Institute
City
Nashville
State/Province
Tennessee
ZIP/Postal Code
37203
Country
United States
Facility Name
Texas Oncology - Austin Midtown
City
Austin
State/Province
Texas
ZIP/Postal Code
78705
Country
United States
Facility Name
Texas Oncology - Medical City Dallas
City
Dallas
State/Province
Texas
ZIP/Postal Code
75230
Country
United States
Facility Name
Texas Oncology - Flower Mound
City
Flower Mound
State/Province
Texas
ZIP/Postal Code
75028
Country
United States
Facility Name
Brooke Army Medical Center
City
Fort Sam Houston
State/Province
Texas
ZIP/Postal Code
78234
Country
United States
Facility Name
Texas Oncology - Fort Worth 12th Avenue
City
Fort Worth
State/Province
Texas
ZIP/Postal Code
76104
Country
United States
Facility Name
MD Anderson Cancer Center / University of Texas
City
Houston
State/Province
Texas
ZIP/Postal Code
77030-4095
Country
United States
Facility Name
Texas Oncology - San Antonio Medical Center
City
San Antonio
State/Province
Texas
ZIP/Postal Code
78240
Country
United States
Facility Name
Texas Oncology - Northeast Texas
City
Tyler
State/Province
Texas
ZIP/Postal Code
75702
Country
United States
Facility Name
Huntsman Cancer Institute/University of Utah
City
Salt Lake City
State/Province
Utah
ZIP/Postal Code
84112
Country
United States
Facility Name
Virginia Cancer Specialists, PC
City
Fairfax
State/Province
Virginia
ZIP/Postal Code
22031
Country
United States
Facility Name
Oncology and Hematology Assoc of SW VA DBA Blue Ridge Cancer Care
City
Salem
State/Province
Virginia
ZIP/Postal Code
24153
Country
United States
Facility Name
Kadlec Clinic Hematology and Oncology
City
Kennewick
State/Province
Washington
ZIP/Postal Code
99336
Country
United States
Facility Name
Vista Oncology Inc PS
City
Olympia
State/Province
Washington
ZIP/Postal Code
98506
Country
United States
Facility Name
Seattle Cancer Care Alliance / University of Washington
City
Seattle
State/Province
Washington
ZIP/Postal Code
98109-1023
Country
United States
Facility Name
Royal Adelaide Hospital
City
Adelaide
State/Province
Other
ZIP/Postal Code
5000
Country
Australia
Facility Name
Ballarat Regional Integrated Cancer Care
City
Ballarat
State/Province
Other
ZIP/Postal Code
3350
Country
Australia
Facility Name
Monash Medical Centre
City
Clayton
State/Province
Other
ZIP/Postal Code
3168
Country
Australia
Facility Name
Epworth Healthcare
City
Victoria
State/Province
Other
ZIP/Postal Code
3002
Country
Australia
Facility Name
Fakultni nemocnice Hradec Kralove-oddeleni klinicke hematologie
City
Hradec Kralove
State/Province
Other
ZIP/Postal Code
500 05
Country
Czechia
Facility Name
Fakultni Nemocnice Kralovske Vinohrady
City
Praha 10
State/Province
Other
ZIP/Postal Code
100 34
Country
Czechia
Facility Name
Azienda Ospedaliera Spedali Civili di Brescia
City
Brescia
State/Province
Other
ZIP/Postal Code
25123
Country
Italy
Facility Name
IRCSS Policlinico San Matteo
City
Pavia
State/Province
Other
ZIP/Postal Code
27100
Country
Italy
Facility Name
Azienda Ospedaliera Universitaria Senese
City
Siena
State/Province
Other
ZIP/Postal Code
53100
Country
Italy
Facility Name
Azienda Ospedaliera Citta della Salute e della Scienza di Torino
City
Torino
State/Province
Other
ZIP/Postal Code
10126
Country
Italy
Facility Name
Pratia MCM Krakow
City
Krakow
State/Province
Other
ZIP/Postal Code
30-727
Country
Poland
Facility Name
Hospital del Mar
City
Barcelona
State/Province
Other
ZIP/Postal Code
08003
Country
Spain
Facility Name
Hospital Universitario Vall d'Hebron
City
Barcelona
State/Province
Other
ZIP/Postal Code
08035
Country
Spain
Facility Name
Institut Catala d'Oncologia - Hospital Duran i Reynals (ICO L'Hospitalet)
City
Barcelona
State/Province
Other
ZIP/Postal Code
08908
Country
Spain
Facility Name
Hospital Universitario de Girona Doctor Josep Trueta
City
Girona
State/Province
Other
ZIP/Postal Code
17007
Country
Spain
Facility Name
Hospital Universitario Fundacion Jimenez Diaz
City
Madrid
State/Province
Other
ZIP/Postal Code
28040
Country
Spain
Facility Name
Hospital Universitario 12 de Octubre
City
Madrid
State/Province
Other
ZIP/Postal Code
28041
Country
Spain
Facility Name
Hospital Puerta de Hierro Majadahonda
City
Majadahonda
State/Province
Other
ZIP/Postal Code
28222
Country
Spain
Facility Name
Hospital Universitario Central de Asturias
City
Oviedo
State/Province
Other
ZIP/Postal Code
33011
Country
Spain
Facility Name
Hospital Clinico Universitario de Salamanca
City
Salamanca
State/Province
Other
ZIP/Postal Code
37007
Country
Spain
Facility Name
Hospital Universitari i Politecnic La Fe de Valencia
City
Valencia
State/Province
Other
ZIP/Postal Code
46026
Country
Spain

12. IPD Sharing Statement

Learn more about this trial

Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma

We'll reach out to this number within 24 hrs